EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Developing Synthetic Full-Length SARS-CoV-2 cDNAs and Reporter Viruses for High-Throughput Antiviral Drug Screening

Megha Rohamare, Nidhi Kaushik, Juveriya Qamar Khan, Mahrokh Balouchi, Joaquin Lopez-Orozco iD, Robert Kozak, Tom C Hobman, Darryl Falzarano iD, Anil Kumar iD, Joyce A Wilson iD

Viruses · 27.12.2025 · 18 (1) · 44

DOI: 10.3390/v18010044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 27.12.2025. Verfasst von Megha Rohamare und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Microbiology, and Immunology, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, High-Throughput Screening Assays, DNA, Complementary. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research (CIHR)-funded Coronavirus Variants Rapid Response Network (CoVaRR-Net), CIHR Operating COVID-19 Rapid Research Funding Opportunity-Therapeutics, CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The continuing spread of SARS-CoV-2 and the associated morbidity and mortality, especially in vulnerable populations, highlight the need for the development of antiviral therapeutics. Reverse genetics systems and reporter viruses are valuable for antiviral screening by simplifying methods to detect and quantify virus infections. This study aimed to generate wild-type and Nluc reporter full-length SARS-CoV-2 molecular clones and viruses as tools for high-throughput antiviral assays. The large SARS-CoV-2 genome (~30 kb) makes cDNA cloning and virus rescue technically challenging, so we opted to use cDNA chemical synthesis services to generate full-length wild-type and reporter Delta and Omicron clones. Clone-derived Delta and Omicron wild-type and reporter viruses were successfully rescued and showed replication kinetics comparable to patient-derived isolates. Nluc reporter viruses displayed stable luciferase expression that correlated with viral titres, supporting their reliability as replication substitutes. Antiviral assays measuring replication inhibition by Remdesivir, Molnupiravir, and Nirmatrelvir, based on Nluc expression, yielded IC50 values and selectivity indices consistent with published ranges. Finally, Delta Nluc viruses replicated in primary human bronchial epithelial cells, demonstrating the application of clone-derived viruses in physiologically relevant models. The SARS-CoV-2 cDNA clones and Nluc reporter viruses derived from DNA synthesis services provide a rapid, scalable reverse genetics platform for generating new viruses and developing assays to rapidly assess antiviral compounds against current and emerging SARS-CoV-2 variants or coronaviruses that may emerge in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsSARS-CoV-2High-Throughput Screening AssaysDNA, ComplementaryHumansGenes, ReporterVirus ReplicationAnimalsDrug Evaluation, PreclinicalReverse GeneticsGenome, ViralChlorocebus aethiopsCOVID-19 Drug TreatmentVero CellsCOVID-19Cell LineAdenosine MonophosphateAlanineCytidineHydroxylamines

Stichwörter der Autor:innen

COVID-19SARS-CoV-2coronavirusluciferasereporter

Substanzen

Antiviral AgentsDNA, ComplementarymolnupiravirremdesivirAdenosine MonophosphateAlanineCytidineHydroxylamines

Autor:innen und Institutionen

  • Department of Biochemistry, Microbiology, and Immunology, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
  • Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada.
  • Department of Cell Biology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
  • Biological Sciences, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.
  • Shared Hospital Laboratory, Toronto, ON M1E 4B9, Canada.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada.

ORCID-Profile: Joaquin Lopez-Orozco, Darryl Falzarano, Anil Kumar, Joyce A Wilson

Förderung

  • Canadian Institutes of Health Research (CIHR)-funded Coronavirus Variants Rapid Response Network (CoVaRR-Net)
  • CIHR Operating COVID-19 Rapid Research Funding Opportunity-Therapeutics
  • CIHR
  • Natural Sciences and Engineering Research Council of Canada
  • Government of Saskatchewan
  • Government of Canada
  • University of Saskatchewan, College of Medicine
  • CIHR Operating COVID-19 Rapid Research Funding Opportunity—Therapeutics

Zitieren

APA

Rohamare, M., Kaushik, N., Khan, J. Q., Balouchi, M., Lopez-Orozco, J., Kozak, R., Hobman, T. C., Falzarano, D., Kumar, A., & Wilson, J. A. (2025). Developing Synthetic Full-Length SARS-CoV-2 cDNAs and Reporter Viruses for High-Throughput Antiviral Drug Screening. Viruses, 18(1), 44. https://doi.org/10.3390/v18010044

Vancouver

Rohamare M, Kaushik N, Khan JQ, Balouchi M, Lopez-Orozco J, Kozak R, et al. Developing Synthetic Full-Length SARS-CoV-2 cDNAs and Reporter Viruses for High-Throughput Antiviral Drug Screening. Viruses. 2025;18(1):44. doi:10.3390/v18010044

BibTeX
@article{Rohamare2025,
  author = {Rohamare, Megha and Kaushik, Nidhi and Khan, Juveriya Qamar and Balouchi, Mahrokh and Lopez-Orozco, Joaquin and Kozak, Robert and Hobman, Tom C and Falzarano, Darryl and Kumar, Anil and Wilson, Joyce A},
  title = {Developing Synthetic Full-Length SARS-CoV-2 cDNAs and Reporter Viruses for High-Throughput Antiviral Drug Screening},
  journal = {Viruses},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {44},
  doi = {10.3390/v18010044}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche